The U.S. Food and Drug Administration.
On 6/10/24, the FDA convened its Peripheral and Central Nervous System Drugs Advisory Committee to review the data from pivotal clinical trials of donanemab, one of which was conducted at UCI MIND. Click to read the full commentary about an FDA-convened advisory panel’s recommendations related to donanemab written by UCI MIND director, Dr. Joshua Grill or visit UCI MIND blog.